2024
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCD79 AntigensHumansImmunoconjugatesLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL